Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

Uloženo v:

Podrobná bibliografie
Hlavní autoři:	Sai‐Hong Ignatius Ou, Ramaswamy Govindan, Keith D. Eaton, Gregory A. Otterson, Martin Gutierrez, Alain C. Mita, Athanassios Argiris, Nicoletta Brega, Tiziana Usari, Weiwei Tan, Steffan N. Ho, Francisco Robert
Médium:	Artigo
Jazyk:	angličtina
Vydáno:	2016
On-line přístup:	https://doi.org/10.1016/j.jtho.2016.09.131 http://www.jto.org/article/S1556086416311194/pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Autor: Ou, Sai-Hong Ignatius, a další
Vydáno: (2016)

Spontaneous Regression of Crizotinib-Associated Complex Renal Cysts During Continuous Crizotinib Treatment
Autor: Klempner, Samuel J., a další
Vydáno: (2014)

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Autor: Alexander Drilon, a další
Vydáno: (2020)

Crizotinib in Patients With MET-Amplified NSCLC
Autor: D. Ross Camidge, a další
Vydáno: (2021)

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
Autor: Drilon, Alexander, a další
Vydáno: (2020)

Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants
Autor: Xu, Huiping, a další
Vydáno: (2021)

Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer
Autor: O’Mahar, Shannon E., a další
Vydáno: (2011)

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
Autor: Sai‐Hong Ignatius Ou
Vydáno: (2011)

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
Autor: Ou, Sai-Hong Ignatius
Vydáno: (2011)

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer
Autor: El‑Khoueiry, Anthony B., a další
Vydáno: (2018)

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (PROFILE 1005 and 1007)
Autor: Ou, Sai‐Hong Ignatius, a další
Vydáno: (2016)

Heart rate decrease during crizotinib treatment and potential correlation to clinical response
Autor: Sai‐Hong Ignatius Ou, a další
Vydáno: (2013)

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (<scp>PROFILE</scp> 1005 and 1007)
Autor: Sai‐Hong Ignatius Ou, a další
Vydáno: (2016)

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib
Autor: Sai‐Hong Ignatius Ou, a další
Vydáno: (2011)

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Autor: Benjamin Solomon, a další
Vydáno: (2014)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Autor: Makoto Nishio, a další
Vydáno: (2017)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Autor: Nishio, Makoto, a další
Vydáno: (2018)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
Autor: Yoshimura, Katsuhiro, a další
Vydáno: (2017)

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function
Autor: Van Der Steen, Nele, a další
Vydáno: (2020)

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
Autor: Maria Carmela Piccirillo, a další
Vydáno: (2022)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
Autor: Zhu, Viola W, a další
Vydáno: (2019)

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer
Autor: Li, Tianhong, a další
Vydáno: (2016)

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
Autor: A. Shaw, a další
Vydáno: (2019)

Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
Autor: Ou, Sai-Hong Ignatius, a další
Vydáno: (2012)

Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis
Autor: Ou, Sai-Hong Ignatius, a další
Vydáno: (2015)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
Autor: Honeywell, Richard J., a další
Vydáno: (2020)

Crizotinib for the Treatment of <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
Autor: Sai‐Hong Ignatius Ou, a další
Vydáno: (2012)

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
Autor: Alice T. Shaw, a další
Vydáno: (2014)

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Autor: Giorgio V. Scagliotti, a další
Vydáno: (2015)

Alectinib Induces a Durable (&gt;15 Months) Complete Response in an <i>ALK</i>-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis
Autor: Sai‐Hong Ignatius Ou, a další
Vydáno: (2015)

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
Autor: Yi‐Long Wu, a další
Vydáno: (2018)

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Autor: Daniel B. Costa, a další
Vydáno: (2011)

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
Autor: Zhang, Yongchang, a další
Vydáno: (2022)

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
Autor: Weickhardt, Andrew J., a další
Vydáno: (2013)

Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations
Autor: Rafael Caparica, a další
Vydáno: (2016)

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients
Autor: Andrew Weickhardt, a další
Vydáno: (2013)

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR -Mutant Lung Cancer Harboring De Novo MET Amplification
Autor: Justin F. Gainor, a další
Vydáno: (2016)

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Autor: Mark A. Socinski, a další
Vydáno: (2018)

Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer
Autor: Gross, Neil D., a další
Vydáno: (2014)

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
Autor: Neil D. Gross, a další
Vydáno: (2014)